ORLANDO, FLA.—In patients with relapsed or refractory mantle cell lymphoma and few remaining treatment options, a chimeric antigen receptor (CAR) T-cell therapy is producing durable responses in the phase 2 ZUMA-2 trial. Against an expected survival of six months, 86% of treated patients were alive, 71% without progression of their disease at 12 months.
“The majority of patients treated so far have achieved a complete response, and the toxicity profile has been manageable,”